Announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily Immediate Release formulation. Camlipixant is the Company’s twice-daily, oral P2X3 antagonist product candidate for the treatment of RCC currently being investigated in the CALM Phase 3 program. BELLUS Health Inc. shares T.BLU are trading down $0.29 at $9.04.
Stocks in play: BELLUS Health Inc.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
/Chipset%20held%20over%20rush%20hour%20traffic%20by%20Jae%20Young%20Ju%20via%20iStock.jpg)
/Meta%20by%20creativeneko%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)